Literature DB >> 10768602

Novel investigative approaches for advanced renal cell carcinoma.

W J Berg1, C R Divgi, D M Nanus, R J Motzer.   

Abstract

Metastatic renal cell carcinoma remains one of the most treatment-resistant malignancies in humans. As such, long-term survival is limited to a minority of patients. Interferon-alpha and interleukin-2 induced major responses in some patients with renal cell carcinoma, and in so doing generated a great deal of interest and hope. However, clinical benefit is limited to relatively few patients. Here, we briefly discuss the management of metastatic renal cell carcinoma, and then elaborate on several novel treatment approaches in development, including retinoids, monoclonal antibodies, and antiangiogenesis strategies.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10768602

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


  8 in total

Review 1.  Allogeneic stem-cell transplantation in renal-cell carcinoma.

Authors:  B M Hayes-Lattin; R T Maziarz; T M Beer
Journal:  Curr Oncol Rep       Date:  2001-09       Impact factor: 5.075

2.  Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers.

Authors:  A N Young; M B Amin; C S Moreno; S D Lim; C Cohen; J A Petros; F F Marshall; A S Neish
Journal:  Am J Pathol       Date:  2001-05       Impact factor: 4.307

3.  Retinoid- and sodium-butyrate-induced decrease in heat shock protein 70 membrane-positive tumor cells is associated with reduced sensitivity to natural killer cell lysis, growth delay, and altered growth morphology.

Authors:  Mathias Gehrmann; Johann Schönberger; Tanja Zilch; Lydia Rossbacher; Gerald Thonigs; Christoph Eilles; Gabriele Multhoff
Journal:  Cell Stress Chaperones       Date:  2005       Impact factor: 3.667

4.  Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma.

Authors:  G Deplanque; S Madhusudan; P H Jones; S Wellmann; K Christodoulos; D C Talbot; T S Ganesan; A Blann; A L Harris
Journal:  Br J Cancer       Date:  2004-11-01       Impact factor: 7.640

5.  Differential expression of microRNA501-5p affects the aggressiveness of clear cell renal carcinoma.

Authors:  Alessandra Mangolini; Anna Bonon; Stefano Volinia; Giovanni Lanza; Roberto Gambari; Paolo Pinton; Gian Rosario Russo; Laura Del Senno; Lucio Dell'Atti; Gianluca Aguiari
Journal:  FEBS Open Bio       Date:  2014-11-04       Impact factor: 2.693

6.  Targeted Therapy for Metastatic Renal Carcinoma: an Update.

Authors:  Rodrigo Donalisio da Silva; Diedra Gustafson; Leticia Nogueira; Priya N Werahera; Wilson R Molina; Fernando J Kim
Journal:  J Kidney Cancer VHL       Date:  2014-10-21

7.  On the role of transforming growth factor-beta in the growth inhibitory effects of retinoic acid in human pancreatic cancer cells.

Authors:  Brahmchetna Singh; Richard F Murphy; Xian-Zhong Ding; Alexandra B Roginsky; Richard H Bell; Thomas E Adrian
Journal:  Mol Cancer       Date:  2007-12-24       Impact factor: 27.401

8.  Androgen receptor (AR) suppresses miRNA-145 to promote renal cell carcinoma (RCC) progression independent of VHL status.

Authors:  Yuan Chen; Yin Sun; Qun Rao; Hua Xu; Lei Li; Chawnshang Chang
Journal:  Oncotarget       Date:  2015-10-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.